{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T01:31:11Z","timestamp":1770514271921,"version":"3.49.0"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.critrevonc.2021.103326","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T22:10:40Z","timestamp":1618956640000},"page":"103326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["The impact of modern radiotherapy on radiation-induced late sequelae: Focus on early-stage mediastinal classical Hodgkin Lymphoma. A critical review by the Young Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)"],"prefix":"10.1016","volume":"161","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1390-4191","authenticated-orcid":false,"given":"Giuseppe Carlo","family":"Iorio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viola","family":"Salvestrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7275-7908","authenticated-orcid":false,"given":"Paolo","family":"Borghetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"De Felice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Greco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7347-0965","authenticated-orcid":false,"given":"Valerio","family":"Nardone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9947-9650","authenticated-orcid":false,"given":"Fabiana","family":"Gregucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isacco","family":"Desideri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.critrevonc.2021.103326_bib0005","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin\u2019s disease","volume":"21","author":"Aleman","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103326_bib0010","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin Lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.critrevonc.2021.103326_bib0015","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin Lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103326_bib0020","series-title":"A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy in Patients with Newly Diagnosed Early Stage","year":"2021"},{"issue":"7","key":"10.1016\/j.critrevonc.2021.103326_bib0025","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMra1003733","article-title":"Early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Armitage","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103326_bib0030","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijrobp.2015.01.013","article-title":"Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both?","volume":"92","author":"Aznar","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"Spring 4","key":"10.1016\/j.critrevonc.2021.103326_bib0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.14338\/IJPT-19-00052.1","article-title":"Cardiac MRI for detecting early cardiac toxicity after proton therapy for Hodgkin Lymphoma","volume":"5","author":"Bates","year":"2019","journal-title":"Int. J. Part. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103326_bib0040","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13014-018-1066-2","article-title":"Proton versus photon deep inspiration breath hold technique in patients with Hodgkin Lymphoma and mediastinal radiation : a planning comparison of deep inspiration breath hold intensity modulation radiotherapy and intensity modulated proton therapy","volume":"13","author":"Baues","year":"2018","journal-title":"Radiat. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103326_bib0045","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijrobp.2012.09.001","article-title":"Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship","volume":"86","author":"Berrington de Gonzalez","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"14","key":"10.1016\/j.critrevonc.2021.103326_bib0050","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin\u2019s disease: long-term results","volume":"22","author":"Bonadonna","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103326_bib0055","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103326_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of Nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin study group NIVAHL trial","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2021.103326_bib0065","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2009.25.3260","article-title":"Treatment of favorable, limited-stage Hodgkin\u2019s lymphoma with chemotherapy without consolidation by radiation therapy","volume":"28","author":"Canellos","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103326_bib0070","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.prro.2013.07.015","article-title":"Active breathing control for patients receiving mediastinal radiation therapy for lymphoma: impact on normal tissue dose","volume":"4","author":"Charpentier","year":"2014","journal-title":"Pract. Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103326_bib0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijrobp.2016.10.004","article-title":"Secondary breast cancer risk by radiation volume in women with Hodgkin Lymphoma","volume":"97","author":"Conway","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103326_bib0080","doi-asserted-by":"crossref","first-page":"djv008","DOI":"10.1093\/jnci\/djv008","article-title":"Risk of valvular heart disease after treatment for Hodgkin lymphoma","volume":"107","author":"Cutter","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"issue":"16","key":"10.1016\/j.critrevonc.2021.103326_bib0085","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","article-title":"Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines","volume":"132","author":"Dabaja","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103326_bib0090","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ijrobp.2009.09.064","article-title":"Radiation-related heart disease: current knowledge and future prospects","volume":"76","author":"Darby","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"26","key":"10.1016\/j.critrevonc.2021.103326_bib0095","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1200\/JCO.2008.19.9174","article-title":"Breast cancer risk in female survivors of Hodgkin\u2019s Lymphoma: lower risk after smaller radiation volumes","volume":"27","author":"De Bruin","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103326_bib0100","article-title":"Adoption of expansion margins to reduce the dose received by the coronary arteries and the risk of cardiovascular events in lymphoma patients","author":"De Luca","year":"2020","journal-title":"Pract. Radiat. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103326_bib0105","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.ijrobp.2018.11.013","article-title":"Early changes in cardiovascular biomarkers with contemporary thoracic radiation therapy for breast Cancer, lung cancer, and lymphoma","volume":"103","author":"Demissei","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2021.103326_bib0110","series-title":"Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study","author":"Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study","year":"2021"},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103326_bib0115","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-73-6-881","article-title":"Combination chemotherapy in the treatment of advanced Hodgkin\u2019s disease","volume":"73","author":"Devita","year":"1970","journal-title":"Ann. Intern. Med."},{"issue":"16","key":"10.1016\/j.critrevonc.2021.103326_bib0120","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.2002.09.038","article-title":"Second malignant neoplasms among long-term survivors of Hodgkin\u2019s disease: a population-based evaluation over 25 years","volume":"20","author":"Dores","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103326_bib0125","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2014-05-575092","article-title":"Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?","volume":"125","author":"Dunleavy","year":"2015","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.critrevonc.2021.103326_bib0130","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"27","key":"10.1016\/j.critrevonc.2021.103326_bib0135","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 4","key":"10.1016\/j.critrevonc.2021.103326_bib0140","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2021.103326_bib0145","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"Engert","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2021.103326_bib0150","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103326_bib0155","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijrobp.2009.10.058","article-title":"Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer","volume":"79","author":"Feng","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"19","key":"10.1016\/j.critrevonc.2021.103326_bib0160","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin\u2019s disease","volume":"357","author":"Ferm\u00e9","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"186","key":"10.1016\/j.critrevonc.2021.103326_bib0165","article-title":"Different IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin\u2019s Lymphoma: dosimetric comparison and clinical considerations","volume":"7","author":"Fiandra","year":"2012","journal-title":"Radiat. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103326_bib0170","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.prro.2012.12.006","article-title":"Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation therapy","volume":"3","author":"Filippi","year":"2013","journal-title":"Pract. Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103326_bib0175","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijrobp.2015.02.030","article-title":"Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk","volume":"92","author":"Filippi","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103326_bib0180","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijrobp.2017.09.039","article-title":"Intensity modulated radiation therapy and second cancer risk in adults","volume":"100","author":"Filippi","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103326_bib0185","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13014-020-01504-8","article-title":"Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin\u2019s lymphoma involving the mediastinum","volume":"15","author":"Filippi","year":"2020","journal-title":"Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103326_bib0190","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijrobp.2011.05.078","article-title":"Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy","volume":"83","author":"Fox","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103326_bib0195","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/annonc\/mdl302","article-title":"Second malignancy risk associated with treatment of Hodgkin\u2019s lymphoma: meta-analysis of the randomised trials","volume":"17","author":"Franklin","year":"2006","journal-title":"Ann. Oncol."},{"issue":"31","key":"10.1016\/j.critrevonc.2021.103326_bib0200","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin Lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin study group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"3 Suppl","key":"10.1016\/j.critrevonc.2021.103326_bib0205","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ijrobp.2009.04.093","article-title":"Radiation dose-volume effects in the heart","volume":"76","author":"Gagliardi","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"33","key":"10.1016\/j.critrevonc.2021.103326_bib0210","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1200\/JCO.20.00935","article-title":"Consolidation radiotherapy could be safely omitted in advanced Hodgkin Lymphoma with large nodal mass in complete metabolic response after ABVD: final analysis of the randomized GITIL\/FIL HD0607 trial","volume":"38","author":"Gallamini","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103326_bib0215","doi-asserted-by":"crossref","first-page":"S566","DOI":"10.1016\/S0167-8140(19)31443-4","article-title":"PO-1023 Continuous Positive Airway Pressure for respiratory gating in lymphomas: a workflow analysis","volume":"133","author":"Giglioli","year":"2019","journal-title":"Radiother. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103326_bib0220","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines","volume":"79","author":"Girinsky","year":"2006","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103326_bib0225","series-title":"Proceedings of the Eighteenth Annual Symposium on Fundamental Cancer Research","article-title":"Radiation biology and cancer","year":"1965"},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103326_bib0230","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.ijrobp.2017.03.026","article-title":"Late cardiac toxicity after mediastinal radiation therapy for hodgkin lymphoma: contributions of coronary artery and whole heart dose-volume variables to risk prediction","volume":"98","author":"Hahn","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103326_bib0235","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0360-3016(03)00073-7","article-title":"Radiation-induced second cancers: the impact of 3D-CRT and IMRT","volume":"56","author":"Hall","year":"2003","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103326_bib0240","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijrobp.2011.12.034","article-title":"Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma","volume":"84","author":"Hoppe","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"9","key":"10.1016\/j.critrevonc.2021.103326_bib0245","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1093\/annonc\/mdx287","article-title":"Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma","volume":"28","author":"Hoppe","year":"2017","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103326_bib0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.prro.2019.09.015","article-title":"The meaningless meaning of mean heart dose in Mediastinal Lymphoma in the modern radiation therapy era","volume":"10","author":"Hoppe","year":"2020","journal-title":"Pract. Radiat. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2021.103326_bib0255","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1001\/jama.290.21.2831","article-title":"Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin Lymphoma treated with radiation therapy","volume":"290","author":"Hull","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2021.103326_bib0260","series-title":"Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)","author":"IELSG37: A Randomized, Open-label, Multicentre","year":"2021"},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103326_bib0265","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ijrobp.2015.11.046","article-title":"Radiation-related new primary solid cancers in the childhood cancer survivor study: comparative radiation dose response and modification of treatment effects","volume":"94","author":"Inskip","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"23","key":"10.1016\/j.critrevonc.2021.103326_bib0270","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.jacc.2013.01.090","article-title":"Cardiac complications of thoracic irradiation","volume":"61","author":"Jaworski","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.critrevonc.2021.103326_bib0275","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1148\/78.4.553","article-title":"The radical radiotherapy of regionally localized Hodgkin\u2019s disease","volume":"78","author":"Kaplan","year":"1962","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103326_bib0280","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s004110100106","article-title":"On the conversion of solid cancer excess relative risk into lifetime attributable risk","volume":"40","author":"Kellerer","year":"2001","journal-title":"Radiat. Environ. Biophys."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103326_bib0285","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.semradonc.2009.09.001","article-title":"Radiation-related treatment effects across the age spectrum: differences and similarities or what the old and young can learn from each other","volume":"20","author":"Krasin","year":"2010","journal-title":"Semin. Radiat. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2021.103326_bib0290","doi-asserted-by":"crossref","first-page":"923-","DOI":"10.1182\/blood.V128.22.923.923","article-title":"Beacoppescalated followed by radiotherapy of initial bulk or residual disease in advanced stage Hodgkin Lymphoma: long-term follow up of the HD9 and HD12 trials of the German Hodgkin study group","volume":"128","author":"Kreissl","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103326_bib0295","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1080\/10428194.2018.1540781","article-title":"Survivors\u2019 perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group","volume":"60","author":"Kreissl","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103326_bib0300","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ijrobp.2017.07.016","article-title":"Breast cancer risk after radiation therapy for hodgkin lymphoma: influence of gonadal hormone exposure","volume":"99","author":"Krul","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"11","key":"10.1016\/j.critrevonc.2021.103326_bib0305","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2016-03-703470","article-title":"Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma","volume":"128","author":"Kumar","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103326_bib0310","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/bjh.16232","article-title":"No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy","volume":"188","author":"Lagerl\u00f6f","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103326_bib0315","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.radonc.2018.04.014","article-title":"Plan optimization for mediastinal radiotherapy: estimation of coronary arteries motion with ECG-gated cardiac imaging and creation of compensatory expansion margins","volume":"127","author":"Levis","year":"2018","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103326_bib0320","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.radonc.2019.05.009","article-title":"Inclusion of heart substructures in the optimization process of volumetric modulated arc therapy techniques may reduce the risk of heart disease in Hodgkin\u2019s lymphoma patients","volume":"138","author":"Levis","year":"2019","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103326_bib0325","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0167-8140(19)30487-6","article-title":"OC-0067 Continuous Positive Airway Pressure (CPAP): an innovative respiratory gating in lymphoma patients","volume":"133","author":"Levis","year":"2019","journal-title":"Radiother. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103326_bib0330","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1200\/JCO.1997.15.6.2275","article-title":"Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin\u2019s disease","volume":"15","author":"Loeffler","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103326_bib0335","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.2015.64.6588","article-title":"Minimizing cardiac risks with contemporary radiation therapy for Hodgkin Lymphoma","volume":"34","author":"Maraldo","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103326_bib0340","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ijrobp.2014.06.069","article-title":"A decade of comparative dose planning studies for early-stage Hodgkin lymphoma: what can we learn?","volume":"90","author":"Maraldo","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103326_bib0345","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/annonc\/mdt156","article-title":"Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma","volume":"24","author":"Maraldo","year":"2013","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2021.103326_bib0350","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/S2352-3026(15)00153-2","article-title":"Cardiovascular disease after treatment for Hodgkin\u2019s lymphoma: an analysis of nine collaborative EORTC-LYSA trials","volume":"2","author":"Maraldo","year":"2015","journal-title":"Lancet Haematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103326_bib0355","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1111961","article-title":"ABVD alone versus radiation-based therapy in Limited-Stage Hodgkin\u2019s Lymphoma","volume":"366","author":"Meyer","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103326_bib0360","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.radonc.2015.07.043","article-title":"Coronary stenosis risk analysis following Hodgkin lymphoma radiotherapy: a study based on patient specific artery segments dose calculation","volume":"117","author":"Moignier","year":"2015","journal-title":"Radiother. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2021.103326_bib0365","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.3324\/haematol.2014.108258","article-title":"Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma","volume":"99","author":"Morton","year":"2014","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.critrevonc.2021.103326_bib0370","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1182\/blood-2014-05-579193","article-title":"Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects","volume":"124","author":"Ng","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103326_bib0375","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2002.08.021","article-title":"Long-term survival and competing causes of death in patients with early-stage Hodgkin\u2019s disease treated at age 50 or younger","volume":"20","author":"Ng","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103326_bib0380","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1200\/JCO.2011.34.5900","article-title":"Distribution of coronary artery stenosis after radiation for breast cancer","volume":"30","author":"Nilsson","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103326_bib0385","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1200\/JCO.2014.58.7543","article-title":"Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base","volume":"33","author":"Olszewski","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103326_bib0390","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ijrobp.2015.06.039","article-title":"Early-stage classic Hodgkin Lymphoma: the utilization of radiation therapy and its impact on overall survival","volume":"93","author":"Parikh","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103326_bib0395","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.ijrobp.2011.05.015","article-title":"Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin\u2019s lymphoma","volume":"82","author":"Paumier","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"17","key":"10.1016\/j.critrevonc.2021.103326_bib0400","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-Directed therapy for early-stage Hodgkin\u2019s Lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103326_bib0405","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2021.103326_bib0410","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1093\/annonc\/mdx356","article-title":"Proton therapy in mediastinal Hodgkin lymphoma: moving from dosimetric prediction to clinical evidence","volume":"28","author":"Ricardi","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103326_bib0415","doi-asserted-by":"crossref","DOI":"10.1016\/S0167-8140(19)30922-3","article-title":"OC-0502 Role of consolidation RT to bulky lesions of advanced Hodgkin lymphoma: results of FIL HD0801 trial","volume":"133","author":"Ricardi","year":"2019","journal-title":"Radiother. Oncol."},{"issue":"8033","key":"10.1016\/j.critrevonc.2021.103326_bib0420","article-title":"Proton therapy for lymphomas: current state of the art","volume":"12","author":"Ricardi","year":"2019","journal-title":"Onco. Ther."},{"issue":"26","key":"10.1016\/j.critrevonc.2021.103326_bib0425","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s Lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103326_bib0430","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.ijrobp.2004.12.040","article-title":"Estimation of radiation-induced cancer from three-dimensional dose distributions: concept of organ equivalent dose","volume":"61","author":"Schneider","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103326_bib0435","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103326_bib0440","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/2040620711402414","article-title":"Long-term survivorship at a price: late-term, therapy-associated toxicities in the adult Hodgkin Lymphoma patient","volume":"2","author":"Straus","year":"2011","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.critrevonc.2021.103326_bib0445","series-title":"Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and\/or Mediastinal Radiotherapy in Patient With Lymphoma","author":"Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and\/or Mediastinal Radiotherapy in Patient With Lymphoma","year":"2021"},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103326_bib0450","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/jnci\/djk029","article-title":"Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study","volume":"99","author":"Swerdlow","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"issue":"31","key":"10.1016\/j.critrevonc.2021.103326_bib0455","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1200\/JCO.2011.34.8268","article-title":"Second cancer risk after chemotherapy for Hodgkin\u2019s lymphoma: a collaborative British cohort study","volume":"29","author":"Swerdlow","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2021.103326_bib0460","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2011.38.8835","article-title":"Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin\u2019s lymphoma in England and Wales: a National Cohort Study","volume":"30","author":"Swerdlow","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"39","key":"10.1016\/j.critrevonc.2021.103326_bib0465","article-title":"Radiation-induced heart disease: pathologic abnormalities and putative mechanisms","volume":"5","author":"Taunk","year":"2015","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103326_bib0470","first-page":"695","article-title":"Lung cancer after Hodgkin lymphoma: the roles of chemotherapy, radiotherapy and tobacco use","volume":"163","author":"Travis","year":"2005","journal-title":"Radiat. Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103326_bib0475","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","article-title":"Lung cancer following chemotherapy and radiotherapy for Hodgkin\u2019s disease","volume":"94","author":"Travis","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103326_bib0480","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jama.290.4.465","article-title":"Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease","volume":"290","author":"Travis","year":"2003","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103326_bib0485","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin Lymphoma","volume":"34","author":"van Nimwegen","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2021.103326_bib0490","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","article-title":"Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines","volume":"129","author":"van Nimwegen","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2021.103326_bib0495","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","article-title":"Dose-intensification in early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial","volume":"30","author":"von Tresckow","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"94","key":"10.1016\/j.critrevonc.2021.103326_bib0500","article-title":"Dosimetric advantages of a \"butterfly\" technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin\u2019s lymphoma","volume":"9","author":"Voong","year":"2014","journal-title":"Radiat. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103326_bib0505","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2005.04.4396","article-title":"Don\u2019t throw out the baby with the bathwater: on optimizing cure and reducing toxicity in Hodgkin\u2019s lymphoma","volume":"24","author":"Yahalom","year":"2006","journal-title":"J. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821001141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821001141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:36:08Z","timestamp":1760902568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842821001141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":101,"alternative-id":["S1040842821001141"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103326","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of modern radiotherapy on radiation-induced late sequelae: Focus on early-stage mediastinal classical Hodgkin Lymphoma. A critical review by the Young Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103326","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103326"}}